Literature DB >> 29579597

Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension.

Stefania Farina1, Noemi Bruno1, Cecilia Agalbato1, Mauro Contini1, Roberto Cassandro2, Davide Elia2, Sergio Harari2, Piergiuseppe Agostoni3.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) patients show, during exercise, an excessive increase in ventilation (VE) compared to carbon dioxide output (VCO2), determining a high VE/VCO2 slope. There are several possible causes, including an elevated dead space ventilation (VD), VE/perfusion (Q) mismatch and/or an enhanced peripheral or central chemoreceptor activity. We evaluated the causes of exercise hyperventilation in PH patients.
METHODS: Eighteen group I and IV PH patients underwent cardiopulmonary exercise test with blood gas analysis at every minute. VE, alveolar ventilation (VA) and VD vs. VCO2 relationship were calculated. Resting chemoreceptor sensitivity was analyzed through hypoxia/hypercapnia tests.
RESULTS: PeakVO2 and VE/VCO2 slopes were 1.06±0.24l/min and 39.1±9.0, respectively. Throughout the exercise, 30% of VE was due to VD. VE/VCO2 slope significantly correlated with VD/VCO2 slope (r=0.82, p<0.001) but not with VA/VCO2 slope (r=0.3, p=ns). Peak exercise end-tidal CO2 (PetCO2) correlated with VD/VCO2 slope (r=-0.79, p<0.001) and VE/VCO2 slope (r=-0.91, p<0.001). Dead space(DS)/Tidal volume and P(arterial-et)CO2 were elevated without arterial hypoxemia suggesting a high VE/Q mismatch. Chemoreceptor peripheral response to hypoxia and central CO2 response were both enhanced being peripheral responses to hypoxia and hypercapnia 0.416±0.402 (normal ref values=0.285±0.221) l/min/O2Sat and 0.076±0.047 (0.066±0.430) l/min/mmHg, respectively; central hypercapnic chemosensitivity was 4.475±3.99 (2.352±0.936) l/min/mmHg.
CONCLUSIONS: Increased DS, VE/Q mismatch and chemorecptor response are among the main mechanisms involved in exercise hyperventilation in PH. ClinicalTrial.govNCT02892981.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chemoreceptors; Dead space ventilation; Pulmonary hypertension; Pulmonary ventilation

Mesh:

Year:  2018        PMID: 29579597     DOI: 10.1016/j.ijcard.2017.11.023

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Carotid chemoreflex activity restrains post-exercise cardiac autonomic control in healthy humans and in patients with pulmonary arterial hypertension.

Authors:  Marcelle Paula-Ribeiro; Indyanara C Ribeiro; Liliane C Aranda; Talita M Silva; Camila M Costa; Roberta P Ramos; Jaquelina S Ota-Arakaki; Sergio L Cravo; Luiz E Nery; Michael K Stickland; Bruno M Silva
Journal:  J Physiol       Date:  2019-01-30       Impact factor: 5.182

Review 2.  Respiratory system as the main determinant of dyspnea in patients with pulmonary hypertension.

Authors:  Ioanna Mitrouska; Maria Bolaki; Katerina Vaporidi; Dimitris Georgopoulos
Journal:  Pulm Circ       Date:  2022-03-23       Impact factor: 2.886

Review 3.  The physiological basis of pulmonary arterial hypertension.

Authors:  Robert Naeije; Manuel J Richter; Lewis J Rubin
Journal:  Eur Respir J       Date:  2022-06-16       Impact factor: 33.795

Review 4.  Measurement and Interpretation of Exercise Ventilatory Efficiency.

Authors:  Devin B Phillips; Sophie É Collins; Michael K Stickland
Journal:  Front Physiol       Date:  2020-06-25       Impact factor: 4.566

5.  Ventricular flow analysis and its association with exertional capacity in repaired tetralogy of Fallot: 4D flow cardiovascular magnetic resonance study.

Authors:  Xiaodan Zhao; Liwei Hu; Shuang Leng; Ru-San Tan; Ping Chai; Jennifer Ann Bryant; Lynette L S Teo; Marielle V Fortier; Tee Joo Yeo; Rong Zhen Ouyang; John C Allen; Marina Hughes; Pankaj Garg; Shuo Zhang; Rob J van der Geest; James W Yip; Teng Hong Tan; Ju Le Tan; Yumin Zhong; Liang Zhong
Journal:  J Cardiovasc Magn Reson       Date:  2022-01-03       Impact factor: 5.364

6.  Bisoprolol and/or hyperoxic breathing do not reduce hyperventilation in pulmonary arterial hypertension patients.

Authors:  Eva L Peters; Jasmijn S J A van Campen; Herman Groepenhoff; Frances S de Man; Anton Vonk Noordegraaf; Harm J Bogaard
Journal:  Pulm Circ       Date:  2021-12-13       Impact factor: 3.017

7.  Role of cardiopulmonary exercise test in the prediction of hemodynamic impairment in patients with pulmonary arterial hypertension.

Authors:  B Pezzuto; R Badagliacca; M Muratori; S Farina; M Bussotti; M Correale; A Bonomi; C Vignati; S Sciomer; S Papa; E Palazzo Adriano; P Agostoni
Journal:  Pulm Circ       Date:  2022-03-24       Impact factor: 2.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.